Hasegawa H. Simultaneous induction of distinct protein phase separation events in multiple subcellular compartments of a single cell. Exp Cell Res. 2019;379:92-109 pubmed publisher

Kamat P, Vandenberghe S, Christen S, Bongoni A, Meier B, Rieben R, et al. Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs. PLoS ONE. 2016;11:e0168541 pubmed publisher

Rharass T, Gbankoto A, Canal C, Kurşunluoğlu G, Bijoux A, Panáková D, et al. Oxidative stress does not play a primary role in the toxicity induced with clinical doses of doxorubicin in myocardial H9c2 cells. Mol Cell Biochem. 2016;413:199-215 pubmed publisher

Yue T, Park K, Reese B, Zhu H, Lyon S, Ma J, et al. Quantifying Drug-Induced Nanomechanics and Mechanical Effects to Single Cardiomyocytes for Optimal Drug Administration To Minimize Cardiotoxicity. Langmuir. 2016;32:1909-19 pubmed publisher

Attia S, Ahmad S, Bakheet S. Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice. Cancer Chemother Pharmacol. 2016;77:27-33 pubmed publisher

Mosesso P, Pepe G, Ottavianelli A, Schinoppi A, Cinelli S. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations. Mutat Res Genet Toxicol Environ Mutagen. 2015;793:14-8 pubmed publisher

Fabbi P, Spallarossa P, Garibaldi S, Barisione C, Mura M, Altieri P, et al. Doxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytes. PLoS ONE. 2015;10:e0124643 pubmed publisher

Sidarovich V, Adami V, Gatto P, Greco V, Tebaldi T, Tonini G, et al. Translational downregulation of HSP90 expression by iron chelators in neuroblastoma cells. Mol Pharmacol. 2015;87:513-24 pubmed publisher

Deng S, Yan T, Nikolova T, Fuhrmann D, Nemecek A, Gödtel Armbrust U, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015;172:2246-57 pubmed publisher

Whelan J, Bielack S, Marina N, Smeland S, Jovic G, Hook J, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26:407-14 pubmed publisher

Aksentijevic D, Zervou S, Faller K, McAndrew D, Schneider J, Neubauer S, et al. Myocardial creatine levels do not influence response to acute oxidative stress in isolated perfused heart. PLoS ONE. 2014;9:e109021 pubmed publisher

Cermanova J, Kadova Z, Dolezelova E, Zagorova M, Safka V, Hroch M, et al. Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats. Shock. 2014;42:372-9 pubmed publisher

Brower V. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer. J Natl Cancer Inst. 2013;105:835-6 pubmed publisher

Doornaert M, Monstrey S, Roche N. Extravasation injuries: current medical and surgical treatment. Acta Chir Belg. 2013;113:1-7 pubmed

Lin R, Ho C, Liu L, Lyu Y. Topoisomerase II? deficiency enhances camptothecin-induced apoptosis. J Biol Chem. 2013;288:7182-92 pubmed publisher

Kovarikova P, Pasakova Vrbatova I, Vavrova A, Stariat J, Klimes J, Simunek T. Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium. J Pharm Biomed Anal. 2013;76:243-51 pubmed publisher

Kang M, Kim K, Song Y, Shin W, Oh J. Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients. J Chemother. 2012;24:292-6 pubmed publisher

Calvé A, Noiles W, Sebag I, Chalifour L. The impact of doxorubicin and dexrazoxane injection of prepubertal female rats on pregnancy outcome and cardiac function postpartum. Can J Physiol Pharmacol. 2012;90:1527-34 pubmed publisher

Eisenberg S. The case of the vexing vesicant. ONS Connect. 2012;27:19 pubmed

Stromberg D, Raymond T, Samuel D, Crockford D, Stigall W, Leonard S, et al. Use of the cardioprotectants thymosin β4 and dexrazoxane during congenital heart surgery: proposal for a randomized, double-blind, clinical trial. Ann N Y Acad Sci. 2012;1270:59-65 pubmed publisher

Vuong M, Hasegawa L, Eastmond D. A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II. Mutat Res. 2013;750:63-71 pubmed publisher

Walker D, Fisher B, Seif A, Huang Y, Torp K, Li Y, et al. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr Blood Cancer. 2013;60:616-20 pubmed publisher

Neckar J, Boudíková A, Mandíková P, Sterba M, Popelova O, Miksik I, et al. Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Can J Physiol Pharmacol. 2012;90:1303-10 pubmed publisher

Tebbi C, Mendenhall N, London W, Williams J, Hutchison R, Fitzgerald T, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012;59:1259-65 pubmed publisher

Drake D. BET 3: emergency management of anthracycline extravasation. Emerg Med J. 2012;29:777-9 pubmed publisher

Harake D, Franco V, Henkel J, Miller T, Lipshultz S. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012;8:647-70 pubmed publisher

Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal. 2013;18:899-929 pubmed publisher

Rabinovich A, Weiss D, Weissman M, Novack V, Levi I. Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients. Am J Hematol. 2012;87:830-2 pubmed publisher

Calvé A, Haddad R, Barama S, Meilleur M, Sebag I, Chalifour L. Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training. Am J Physiol Heart Circ Physiol. 2012;302:H2048-57 pubmed publisher

Zatloukalová L, Filipský T, Mladenka P, Semecky V, Macakova K, Holeckova M, et al. Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity. Can J Physiol Pharmacol. 2012;90:473-84 pubmed publisher

Palacios E, Lam E. Infantile fibrosarcoma of the maxillary sinus: significant response. Ear Nose Throat J. 2012;91:98-100 pubmed

Draenert G, Huetzen D, Kämmerer P, Palarie V, Nacu V, Wagner W. Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo. J Craniomaxillofac Surg. 2012;40:e369-74 pubmed publisher

Sivak L, Askol skiĭ A, Lial kin S, Klimanov M, Maĭdanevich N, Kasap N. [Cardiotoxicity of conservative treatment of solid tumors]. Lik Sprava. 2011;:51-9 pubmed

Lipshultz S, Miller T, Scully R, Lipsitz S, Rifai N, Silverman L, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:1042-9 pubmed publisher

Doroshow J. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012;13:1949-56 pubmed

Fontaine C, Noens L, Pierre P, De Greve J. Savene® (dexrazoxane) use in clinical practice. Support Care Cancer. 2012;20:1109-12 pubmed publisher

Venable R, Saba C, Endicott M, Northrup N. Dexrazoxane treatment of doxorubicin extravasation injury in four dogs. J Am Vet Med Assoc. 2012;240:304-7 pubmed publisher